The mixed data from the Phase III COAST 2 trial follows an underwhelming data drop from COAST 1 in September that Leerink ...

Corxel will use the fundraising proceeds to advance the oral GLP-1 therapy CX11 through mid-stage development in the U.S., as ...

The FDA’s rare pediatric disease priority review voucher program missed reauthorization at the last minute in 2024; advocates ...

I don’t like established science,” ACIP chairperson Kirk Milhoan said in an interview on the Why Should I Trust You? podcast.

The company also stands to gain from recent regulatory FDA guidance aimed at streamlining the development of non-opioid ...

The star of the acquisition, anti-IgE antibody ozureprubart, is being tested as a prophylactic treatment for food allergies, ...

As drug candidates discovered via AI move into later-stage clinical trials, the technology seems to be doing as promised: ...

Following the hard-won success of early anti-amyloid drugs, a new generation of Alzheimer’s modalities—from tau-targeting ...

Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment ...

Pfizer CEO Albert Bourla said that the main thing getting in the way of changing vaccine discussions in the U.S. is the ...

After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will ...

Despite the late-stage miss, analysts maintained confidence in the Epkinly program, with Truist Securities saying the result ...